Download PDF
Dtsch Med Wochenschr 2005; 130(46): 2645-2650
DOI: 10.1055/s-2005-922049
Übersichten
Hypertensiologie
© Georg Thieme Verlag Stuttgart · New York

Therapie des adipösen Hypertonikers

Therapy of obesity associated hypertensionJ. Scholze1 , S. Patschan2 , Y. Dörffel1 , A. Hansen1
  • 1Medizinische Poliklinik/Center of Cardiovascular Research/CCM
  • 2New York Medical College, Renal Research Institute, N. Y.
Further Information

Publication History

eingereicht: 4.8.2005

akzeptiert: 7.11.2005

Publication Date:
10 November 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Adipositas geht mit einer ca. 50 %igen Prävalenz hypertoner Blutdruckwerte einher, die in Abhängigkeit vom Body Mass Index bis auf 80 % ansteigt. Ätiopathogenetisch stellt das viszerale Fett mit Aktivierung des Neuroendokrineums (Sympathicus, RAAS), der Induktion einer Insulinresistenz mit Hyperinsulinämie und der direkten medullären Kompression durch Fetteinlagerungen in den Nieren die entscheidende Grundlage für die veränderte Hämodynamik und den Blutdruckanstieg dar. Primäres Ziel ist eine durch Ernährungs- und Lifestyle-Modifikation erzielte, lang anhaltende Gewichtsreduktion, welche ggf. mit gewichtsreduzierenden Medikamenten zu ergänzen sind. Dabei senkt Orlistat zugleich den Blutdruck, was vom Sibutramin nur unter bestimmten Voraussetzungen in speziellen Situationen ausgeht. Interessanterweise steigt der Blutdruck nach gewichtsreduzierenden chirurgischen (bariatrischen) Maßnahmen im Verlaufe von zehn Jahren wieder deutlich trotz anhaltender Gewichtsreduktion an. Die antihypertensive medikamentöse Differentialtherapie sollte sich am pathophysiologischen Realisierungsmuster und den Begleit- und Folgeerkrankungen orientieren. Dabei dürften ACE-Hemmer (alternativ Angiotensin-Rezeptor-Blocker) in Kombination mit niedrig dosierten Diuretika die Priorität geniessen, gefolgt in der Kombination mit Kalziumantagonisten. Beta-Rezeptoren-Blocker sollten immer dann zum Einsatz kommen, wenn eindeutige kardiale Indikationen dafür bestehen.

Summary

There is a 50 % prevalence of obesity with arterial hypertension. This ratio can increase up to 80 %, depending on body mass index. Important pathogenetic origins are quantity of visceral body fat along with the activation of neuroendocrineum (sympathicus, renin-angiotensin system), an induction of insulin resistance with hyperinsulinemia, and a direct compression of the medulla by fat deposits in the kidneys, which results in hemodynamic changes and an increase in blood pressure. The primary aim is a reduction in weight by means of a balanced diet and life style modification, which can be augmented by weight reducing medication. Orlistat lowers blood pressure and body weight simultaneously, whereas sibutramine accomplishes this only under certain circumstances. Interestingly, blood pressure increases again over the course of 10 years following weight reducing surgical procedures, despite ongoing weight loss. Antihypertensive differential therapy should be focused on pathophysiology and concomitant and target organ disease. Thus ACE inhibitors (alternatively angiotensin receptor blockers), in combination with low dose diuretics, should be preferentially administered, followed by calcium antagonists. Beta blockers should be used if definite cardiac indications are present.

Literatur

  • 1 Alpert M A, Lambert C R, Terry B E. et al . Interrelationsship of left ventricular mass, systolic function and diastolic filling in normotensive morbidly obese patients.  Int J Obes. 1995;  19 550-557
    Google Scholar
  • 2 Bakris G, Calhoun D, Egan B. et al . Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension.  J Hypertension. 2002;  20 2257-2267
    Google Scholar
  • 3 Birkenfeld A L, Schroeder C H, Pischon T. et al . Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients. Sibutramine and blood pressure.  Clin Auton Res. 2005;  15 200-206
    Google Scholar
  • 4 Boschmann M, Jordan J, Adams F. et al . Tissue-specific response to interstitial angiotensin II in humans.  Hypertension. 2003;  41 37-41
    Google Scholar
  • 5 Bramlage P, Pittrow D, Wittchen H U. et al . Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled.  Am J Hypertens. 2004;  17 904-910
    Google Scholar
  • 6 Bramlage P, Wittchen H U, Pittrow D. et al . Recognition and management of overweight and obesity in primary care in Germany.  Int J Obes Relat Metab Disord. 2004;  28 1299-1308
    Google Scholar
  • 7 DeFronzo R A, Ferrannini E. Insulin resistance. A multivaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease.  Diabetes Care. 1991;  14 73-194
    Google Scholar
  • 8 Derosa G, Cicero A FG, Murdolo G. et al . Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.  Diabetes, Obesity and Metabolism. 2005;  7 47-55
    Google Scholar
  • 9 Douketis J D, Sharma A M. The Management of hypertension in the overweight and obese patient. Is weight reduction sufficient?.  Drugs. 2004;  64 795-803
    Google Scholar
  • 10 Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A. et al . Human adipocytes secrete mineralocorticoid-releasing factors.  Proc Natl Acad Sci USA. 2003;  100 14211-14216
    Google Scholar
  • 11 Engeli S t, Boehnke J, Gorzelniak K. et al . Weight loss and the renin-angiontensin-aldosterone systeme.  Hypertension. 2005;  45 356-362
    Google Scholar
  • 12 Epstein M. Calcium antagonists and the kidney.  J Cardiovasc Pharmacol. 1994;  24 S18-24 (Suppl A)
    Google Scholar
  • 13 Estacio R O, Jeffers B W, Hiatt W R. et al . The effect of Nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent-diabetes and hypertension.  New Engl J Med. 1998;  338 645-681
    Google Scholar
  • 14 Fogari R, Zoppi A, Lazzari P. et al . ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.  J Cardiovasc Pharmacol. 1998;  32 616-620
    Google Scholar
  • 15 Goodfriend Th L, Calhoun D A. Resistant hypertension, obesity, sleep apnea and aldosterone theory and therapy.  Hypertension. 2004;  43 518-524
    Google Scholar
  • 16 Goodfriend T L, Ball D L, Gardner H W. An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro.  Prostaglandins Leukot Essent Fatty Acids. 2002;  67 163-167
    Google Scholar
  • 17 Goodfriend T L, Egan B M, Kelley D E. Aldosterone in obesity.  Endocr Res. 1998;  24 789-796
    Google Scholar
  • 18 Gregg E W, Cheng Y J, Cadwell B L. et al . Sucular Trends in cardiovascular disease risk factors according to body mass index in US adults.  JAMA. 2005;  293 1868-1874
    Google Scholar
  • 19 Gress T W, Nieto F J, Shahar E. et al . Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.  N Engl J Med. 2000;  342 905-912
    Google Scholar
  • 20 Grossman E, Messerli F H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure.  Am J Cardiol. 1997;  80 1453-1458
    Google Scholar
  • 21 Hall J E. The kidney, hypertension, and obesity.  Hypertension. 2003;  41 625-633
    Google Scholar
  • 22 Hanefeld M, Breidert M. Das metabolische Syndrom - Adipositas und Hypertonie. Wien: Blackwell Wissenschafts-Verlag In: Wechsler G, Hrsg. Adipositas 1998: 131-145
    Google Scholar
  • 23 Helmert U, Strube E. Die Entwicklung der Adipositas in Deutschland im Zeitraum von 1985 bis 2002.  Gesundheitswesen. 2004;  66 409-415
    Google Scholar
  • 24 Hirose H, Saito I, Tsujioka M. et al . The obese gene product, leptin: possible role in obesity-related hypertension in adolescents.  J Hypertens. 1998;  16 2007-2012
    Google Scholar
  • 25 Hu F B, Willett W C, Li T. et al . Adiposity as compared with physical activity in predicting mortality among woman.  N Engl J Med. 2004;  351 2694-2703
    Google Scholar
  • 26 James W P, Astrup A, Finer N. et al . Effect of sibutramine on weight maintenance after weight loss: a randomised trial.  Lancet. 2000;  356 2119-2225
    Google Scholar
  • 27 Jordan J, Scholze J, Matiba B. et al . Influence of sibutramine in blood pressure: evidence from placebo-controlled trials.  Intern J Obes. 2005;  29 1-8
    Google Scholar
  • 28 Klein S, Fontana L, Young L. et al . Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease.  N Engl J Med. 2004;  350 2549-2554
    Google Scholar
  • 29 Kortelainen M L, Särkioia T. Extent and composition of coronary lesions and degree of cardiac hypertrophy in relation to abdominal fatness in men under 40 years of age.  Arterioscler Thromb Vasc Biol. 1997;  17 574-579
    Google Scholar
  • 30 Krotkiewski R J, Björntorp P, Sjöström L. et al . Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution.  J Clin Invest. 1983;  73 1150-1162
    Google Scholar
  • 31 Lewis E J, Hunsicker L G, Clarke W R. et al . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.  N Engl J Med. 2001;  345 851-860
    Google Scholar
  • 32 Lindholm L H, Ibsen H, Dahlöf B. et al. The LIFE Study Group . Cardiovascular morbidity and mortality in subjects with type 2 diabetes with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 1004-1010
    Google Scholar
  • 33 Masuo K, Mikami H, Ogihara T. et al . Familial obesity, sympathetic activation and blood pressure level.  Blood pressure. 2001;  10 199-204
    Google Scholar
  • 34 Masuo K, Mikami H, Ogihara T. et al . Weight reduction and pharmacologic treatment in obese hypertensives.  Am J Hypertens. 2001;  14 530-538
    Google Scholar
  • 35 Messerli F H, Nunez B D, Ventura H O, Snyder D W. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity.  Arch Intern Med. 1987;  147 1725-1728
    Google Scholar
  • 36 Morel Y, Gadient A, Keller U. et al . Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol.  J Cardiovasc Pharmacol. 1995;  26 306-311
    Google Scholar
  • 37 Pepine C J, Handberg E M, Cooper-DeHoff R M. et al . INVEST Investigators: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.  J Am Med Assoc . 2003;  290 2805-2816
    Google Scholar
  • 38 Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity.  N Engl J Med. 1990;  39 167-174
    Google Scholar
  • 39 Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.  N Engl J Med. 1989;  321 868-873
    Google Scholar
  • 40 Reiners C D, Harder T, Nau R C. Nichtmedikamentöse Therapie des metabolischen Syndroms.  Internist. 1996;  37 712-721
    Google Scholar
  • 41 Reisin E, Weir M R, Falkner B, Hutchinson H G, Anzalone D A, Tuck M L. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group.  Hypertension. 1997;  30 140-145
    Google Scholar
  • 42 Ruggenenti P, Fassi A, Ilieva A P. et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators . Preventing microalbuminuria in type 2 diabetes.  N Engl J Med. 2004;  351 1941-1951
    Google Scholar
  • 43 Scaglione R, Ganguzza A, Corrao S. et al . Central obesity and hypertension: pathophysiologic role of renal haemodynamics and function.  Int J Obes. 1995;  19 403-409
    Google Scholar
  • 44 Scholze J. Adipositasbehandlung mit Sibutramin unter Praxisbedingungen. Positive Effekte auf metabolische Parameter und Blutdruck.  Dtsch Med Wochenschr. 2002;  127 605-610
    Google Scholar
  • 45 Sharma A M, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension.  J Hypertens. 2002;  9 1873-1878
    Google Scholar
  • 46 Sharma A M, Pischon T, Hardt S, Kunz I, Luft F C. Beta adrenergic receptor blockers and weight gain: a systematic analysis.  Hypertension. 2001;  37 250-254
    Google Scholar
  • 47 Sjostrom L, Lindroos A K, Peltonen M. et al . Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery.  N Engl J Med. 2004;  26 2683-2693
    Google Scholar
  • 48 Stamler R, Stamler J, Grimm R. et al . Nutritional therapy for high blood pressure: final report of a four-year randomized controlled trial: the Hypertension Control Program.  JAMA. 1987;  257 1484-1491
    Google Scholar
  • 49 Stevens V J, Obarzanek E, Cook N R. et al . Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, Phase II.  Ann Intern Med. 2001;  134 1-11
    Google Scholar
  • 50 Tatti P, Pahor M, Byington R P. et al . Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET).  Diab Care. 1998;  21 597-603
    Google Scholar
  • 51 Temelkova-Kurktschiev T, Schaper F, Kohler K. et al . Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals.  Diabetologia. 1998;  41 706-712
    Google Scholar
  • 52 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  JAMA. 2002;  255 2981-2997
    Google Scholar
  • 53 Torgerson J S, Boldrin M N, Hauptman J. et al . XENical in the prevention of Diabetes in Obese Subjects (XENDOS) Study.  Diabetes Care. 2004;  27 155-161
    Google Scholar
  • 54 Tuck M L, Sowers J, Dornfeld L. et al . The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients.  N Engl J Med. 1981;  304 930-933
    Google Scholar
  • 55 Weyer C, Funahashi T, Tanaka S. et al . Hypoadiponectinemia in obesity and type 2 diabetes close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86 1930-1935
    Google Scholar
  • 56 Whelton P K, Appel L J, Espeland M A. et al . Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE): TONE Collaborative Research Group.  JAMA. 1998;  279 839-846
    Google Scholar
  • 57 Wirth A. Blutdrucksenkung durch Ausdauersport.  Inn Med. 1985;  12 226-230
    Google Scholar

Prof. Dr. med. Jürgen Scholze

Charité - Universitätsmedizin Berlin, Campus Mitte/Medizinische Poliklinik

Luisenstraße 11 - 13

10117 Berlin

Email: juergen.scholze@charite.de

      >